Register Login

SONOMA PHARMACEUTICALS, INC. (SNOA)

SymbolSNOA
NameSONOMA PHARMACEUTICALS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address645 MOLLY LANE,SUITE 150, WOODSTOCK, Georgia, 30189, United States
Telephone+1 800 759-9305
Fax—
Email—
Websitehttps://www.sonomapharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001367083
Description

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries.

Additional info from NASDAQ:
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries.

2026-06-30 13:00

Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution

Read more
2026-06-24 18:18

New Form DEFA14A - Sonoma Pharmaceuticals, Inc. <b>Filed:</b> 2026-06-24 <b>AccNo:</b> 0001683168-26-005092 <b>Size:</b> 26 KB

Read more
2026-06-16 20:15

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results

Read more
2026-05-05 17:56

New Form DEF 14A - Sonoma Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-05 <b>AccNo:</b> 0001683168-26-003495 <b>Size:</b> 1 MB

Read more
2026-04-30 21:00

(99% Neutral) SONOMA PHARMACEUTICALS, INC. (SNOA) Provides Update on offering for general corporate purposes

Read more
2026-04-27 07:03

New Form 424B4 - Sonoma Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001683168-26-003212 <b>Size:</b> 273 KB

Read more
2026-04-24 13:22

Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering

Read more
2026-04-17 18:24

New Form S-1 - Sonoma Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001683168-26-003052 <b>Size:</b> 1 MB

Read more
2026-04-09 12:30

(99% Neutral) SONOMA PHARMACEUTICALS, INC. (SNOA) Announces Business Combination

Read more
2026-03-24 12:30

Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

Read more